Genetics

Hereditary cancer gene panel in Taiwan

遺傳性癌症基因檢測

Inherited mutations that raise cancer risk (e.g. BRCA).

US guidance recommends this mainly with a personal or family history, together with genetic counseling.

About this test

A blood or saliva test that reads a set of genes known to be linked to cancer, such as BRCA. The sample goes to a laboratory that looks for inherited changes in the DNA.

It looks for gene changes passed down in families that can raise the risk of certain cancers. It is mainly used when a person has a personal or family history of cancer, together with genetic counseling.

How much does Hereditary cancer gene panel cost in Taiwan?

In Taiwan, Hereditary cancer gene panel is listed on its own from US$748, typically US$802 at 2 hospitals.

Price on its own

From US$748; typical US$802 across 2 hospitals.

Hospital	City	As listed	Price	Note
E-Da Hospital Health Management Center	Kaohsiung	Next-generation sequencing BRCA1/2 gene test (breast, ovarian, prostate cancer)	US$748 NT$24,000	Source ↗ · checked 2026-09-20
Koo Foundation Sun Yat-Sen Cancer Center	Taipei	Comprehensive hereditary cancer gene panel	US$857 NT$27,500	Source ↗ · checked 2026-09-20

US$ at 32.1 TWD, 23 Sep 2026; you pay in NT$.

What US screening guidelines say

The US Preventive Services Task Force is an independent US panel whose recommendations cover people without symptoms. Shown for comparison; it is not advice for you.

Hereditary cancer gene panel

Recommended (grade A/B)The USPSTF recommends that primary care clinicians assess women with this history using a brief familial risk-assessment tool, and refer those who screen positive for genetic counseling and, if indicated, BRCA testing. (2019; an update is in progress) · USPSTF ↗ Note: The USPSTF addresses BRCA1/2 only: it says the clinical significance of pathogenic variants found on multigene panels requires further investigation, and it did not review evidence on risk assessment or testing in men. The USPSTF lists an update of this topic as in progress; the 2019 statement remains the current final recommendation as of 2026-09-25.

Recommended against (grade D)The USPSTF recommends against routine risk assessment, genetic counseling or genetic testing for women whose personal or family history or ancestry is not associated with potentially harmful BRCA1/2 gene mutations. (2019; an update is in progress) · USPSTF ↗ Note: The USPSTF addresses BRCA1/2 only: it says the clinical significance of pathogenic variants found on multigene panels requires further investigation, and it did not review evidence on risk assessment or testing in men. The USPSTF lists an update of this topic as in progress; the 2019 statement remains the current final recommendation as of 2026-09-25.

Related tests

APOE genotype Pharmacogenomic panel

Browse: Checkups by city, focus and who it's for · What a checkup costs in Taiwan